Fibrinogen mediates bladder cancer cell migration in an ICAM-1-dependent pathway

Summary

Fibrinogen (fg), present in tumor matrices, has been demonstrated to be determinant in metastatic potential. We have recently shown that fg/ICAM-1 interactions are involved in leukocyte migration across endothelial cell monolayers. Using bladder transitional cell carcinoma as a model, we will show in this study that bladder high grade tumor cell lines express ICAM-1, and that this expression induces an fg-mediated migration. This phenomenon was dependent on ICAM-1/fg interaction as well as RhoA activity. ICAM-1 was concentrated in focal adhesion plaques when tumor cells were allowed to adhere on immobilized fg, suggesting a role in cell migration. The addition of fg induced a 3- to 6-fold enhancement of bladder tumor cell migration through HUVEC monolayers. This process was inhibited by an anti-ICAM-1 antibody blocking fg binding, demonstrating that ICAM-1/fg interaction was involved in the extravasation process. Finally, immunohistological studies revealed that the expression of ICAM-1 was closely associated with an infiltrative histological phenotype.

Part of this paper was originally presented as part of the joint meetings of the 16th International Congress of the International Society of Fibrinolysis and Proteolysis (ISFP) and the 17th International Fibrinogen Workshop of the International Fibrinogen Research Society (IFRS) held in Munich, Germany, September, 2002.

Keywords

ICAM-1 - fibrinogen - tumor invasion - metastasis - cell migration

• References

• 1 Liotta LA. Tumor invasion and metastases – role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res 1986; 46 (01) 1-7.
• 2 Brown LF, Van de Water L, Harvey VS, Dvorak HF. Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. Am J Pathol 1988; 130 (03) 455-65.
• 3 Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983; 2 (01) 41-73.
• 4 Dvorak HF, Nagy JA, Berse B. et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci 1992; 667: 101-11.
• 5 Dejana E, Languino LR, Polentarutti N, Balconi G, Ryckewaert JJ, Larrieu MJ. et al. Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. J Clin Invest 1985; 75 (01) 11-8.
• 6 Altieri DC, Mannucci PM, Capitanio AM. Binding of fibrinogen to human monocytes. J Clin Invest 1986; 78 (04) 968-76.
• 7 Hart IR, Goode NT, Wilson RE. Molecular aspects of the metastatic cascade. Biochim Biophys Acta 1989; 989 (01) 65-84.
• 8 Languino LR, Plescia J, Duperray A, Brian AA, Plow EF, Geltosky JE. et al. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell 1993; 73 (07) 1423-34.
• 9 Languino LR, Duperray A, Joganic KJ, Fornaro M, Thornton GB, Altieri DC. Regulation of leukocyte-endothelium interaction and leukocyte transendothelial migration by intercellular adhesion molecule 1- fibrino-gen recognition. Proc Natl Acad Sci U S A 1995; 92 (05) 1505-9.
• 10 Sans E, Delachanal E, Duperray A. Analysis of the roles of ICAM-1 in neutrophil transmigration using a reconstituted mammalian cell expression model: implication of ICAM-1 cytoplasmic domain and Rho-dependent signaling pathway. J Immunol 2001; 166 (01) 544-51.
• 11 Jackson AM, Alexandrov AB, Prescott S, James K, Chisholm GD. Expression of adhesion molecules by bladder cancer cells: modulation by interferon-gamma and tumour necrosis factor-alpha. J Urol 1992; 148 (05) 1583-6.
• 12 Miele ME, Bennett CF, Miller BE, Welch DR. Enhanced metastatic ability of TNF-alpha-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides. Exp Cell Res 1994; 214 (01) 231-41.
• 13 Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hem-atogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002; 62 (23) 6966-72.
• 14 Engvall E, Ruoslahti E. Binding of soluble form of fibroblast surface protein, fibronectin, to collagen. Int J Cancer 1977; 20 (01) 1-5.
• 15 Rigby CC, Franks LM. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure. Br J Cancer 1970; 24 (04) 746-54.
• 16 O’Toole C, Perlmann P, Unsgaard B, Moberger G, Edsmyr F. Cellular immunity to human urinary bladder carcinoma. I. Correlation to clinical stage and radiotherapy. Int J Cancer 1972; 10 (01) 77-91.
• 17 Nayak SK, O’Toole C, Price ZH. A cell line from an anaplastic transitional cell carcinoma of human urinary bladder. Br J Cancer 1977; 35 (02) 142-51.
• 18 O’Toole C, Price ZH, Ohnuki Y, Unsgaard B. Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma. Br J Cancer 1978; 38 (01) 64-76.
• 19 Marshall CJ, Franks LM, Carbonell AW. Markers of neoplastic transformation in epithelial cell lines derived from human carcinomas. J Natl Cancer Inst 1977; 58 (06) 1743-51.
• 20 Perissel B, Benkhalifa M, Taillandier J. et al. Karyotype and FISH analysis of a newly established cell line derived from human bladder carcinoma. Cancer Genet Cytogenet 1993; 67: 101-7.
• 21 Mialhe A, Louis J, Montlevier S. et al. Expression of E-cadherin and alpha-, beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors?. Invasion Metastasis 1997; 17 (03) 124-37.
• 22 Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52 (11) 2745-56.
• 23 Aktories K, Braun U, Rosener S, Just I, Hall A. The rho gene product expressed in E. coli is a substrate of botulinum ADP-ribosyltransferase C3. Biochem Biophys Res Commun 1989; 158 (01) 209-13..
• 24 Hermanek P, Sobin LH. UICC, TNM Classification of Malignant Tumors. Paris: Springer; 1988
• 25 Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. International Histological Classificatin of Tumours, 10. Geneva: World Health Organisation; 1973
• 26 Herrick S, BlancBrude O, Gray A, Laurent G. Fibrinogen. Int J Biochem Cell Biol 1999; 31 (07) 741-6.
• 27 Duperray A, Languino LR, Plescia J. et al. Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging. J Biol Chem 1997; 272 (01) 435-41.
• 28 Nobes CD, Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 1999; 144 (06) 1235-44.
• 29 Etienne S, Adamson P, Greenwood J, Strosberg AD, Cazaubon S, Couraud PO. ICAM-1 signaling pathways associated with Rho activation in microvascular brain endothelial cells. J Immunol 1998; 161 (10) 5755-61.
• 30 Palumbo JS, Kombrinck KW, Drew AF. et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96 (10) 3302-9.
• 31 Drew AF, Liu H, Davidson JM, Daugherty CC, Degen JL. Wound-healing defects in mice lacking fibrinogen. Blood 2001; 97 (12) 3691-8.
• 32 Nagaoka T, Kaburagi Y, Hamaguchi Y. et al. Delayed wound healing in the absence of intercellular adhesion molecule- 1 or L-selec-tin expression. Am J Pathol 2000; 157 (01) 237-47.